[2] 韩肖燕,紘明蓉,曹泽毅,等.134 例原发性宫颈腺癌临床特点及预后分析[J].中国医药导刊,2008,10(1):2-6.
[2] Kasamatsu T,Onda T,Sawada M,et al.Radical hysterectomy for FIGO stage Ⅰ-ⅡB adenocarcinoma of the uterine cervix[J].Br J Cancer,2009,100(9):1400-1405.
[3] Mathew A,George PS.Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix-worldwide [J].Asian Pac J Cancer Prev,2009,10(4):645-650.
[4] Missaoui N,Trabelsi A,Landolsi H,et al.Cervical adenocarcinoma and squamous cell carcinoma incidence trends among Tunisian women[J].Asian Pac J Cancer Prev,2010,11(3):777-780.
[5] 袁光文,吴令英,李晓光,等.宫颈腺鳞癌与宫颈腺癌预后比较及相关因素分析[J].中国肿瘤临床,2009,36(4):188-191.
[6] Ndisang D,Lorenzato F,Sindos M,et al.The HPV cellular transactivator Brn-3a can be used to predict cervical adenocarcinoma and squamous carcinoma precancer lesions in the developed and developing worlds[J].Obstet Gynecol Int,2009:359457,doi:10.1155 /2009 /359457.
[7] Odida M,Sandin S,Mirembe F,et al.HPV types,HIV and invasive cervical carcinoma risk in Kampala,Uganda:a casecontrol study[J].Infect Agent Cancer,2011,6(1):8.
[8] Chaturvedi AK,Kleinerman RA,Hildesheim A,et al.Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix[J].J Clin Oncol,2009,27(6):967-973.
[9] 王喜梅,罗光霞,张雪梅,等.宫颈腺癌HPV16 /18 感染与ki67、p53 蛋白表达的关系[J].实用癌症杂志,2009,1(24):22-25.
[10] 阿依努尔买买提,佐合拉古丽木塔力甫,古扎丽努尔阿不力孜,等.新疆维、汉族宫颈腺癌与HPV 各类型关系的研究[J].新疆医科大学学报,2009,32(5):518-521.
[11] Gong L,Zhang WD,Liu XY,et al.Clonal status and clinicopathological observation of cervical minimal deviation adenocarcinoma[J].Diagn Pathol,2010(5):25.
[12] Chang J,Zhang S,Zhou H,et al.Clinical analysis of minimal deviation adenocarcinoma of the cervix:a report of five cases[J].Ai Zheng,2008,27(12):1310-1314.
[13] Nakamura E,Iwakawa M,Furuta R,et al.Villin1,a novel diagnostic marker for cervical adenocarcinoma[J].Cancer Biol Ther,2009,8(12):1146-1153.
[14] Odida M,Lloveras B,Guimera N,et al.The usefulness of immunohistochemistry in tissue microarrays of human papillomavirus negative adenocarcinoma of the uterine cervix[J].BMC Res Notes,2010,54(3):1756-1760.
[15] 何华,钟玲.联合检测ER、Vimentin、CK8 /18、CEA 对子宫内膜腺癌和宫颈腺癌鉴别诊断的意义[J].中国肿瘤临床,2005,32(7):392-394.
[16] Lin YC,Lin G,Chen YR,et al.Role of magnetic resonance imaging and apparent diffusion coefficient at 3T in distinguishing between adenocarcinoma of the uterine cervix and endometrium[J].Chang Gung Med J,2011,34(1):93-100.
[17] Park HM,Lee SS,Eom DW,et al.Endometrioid adenocarcinoma arising from endometriosis of the uterine cervix:a case report[J].J Korean Med Sci,2009,24(4):767-771.
[18] 董虹,李双,王丹,等.宫颈腺癌与鳞癌生物学行为比较及宫颈腺癌预后相关因素分析[J].华中科技大学学报:医学版,2010,39(2):254-257.
[19] Kim ML,Hahn HS,Lim KT,et al.The safety of conization in the management of adenocarcinoma in situ of the uterine cervix[J].J Gynecol Oncol,2011,22(1):25-31.
[20] Helpman L,Grisaru D,Covens A.Early adenocarcinoma of the cervix:Is radical vaginal trachelectomy safe? [J].Gynecol Oncol,2011,123(1):95-98.
[21] 魏梅,梁立治,袁颂华,等.宫颈腺癌105 例临床分析[J].中国肿瘤临床,2005,32(21):1227-1230.
[22] Park JY,Kim DY,Kim JH,et al.Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix[J].Br J Cancer,2010,102(12):1692-1698.
[23] Niibe Y,Kenjo M,Onishi H,et al.High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage Ⅲb adenocarcinoma of the uterine cervix in Japan:a multiinstitutional study of Japanese Society of Therapeutic Radiology and Oncology 2006-2007(study of JASTRO 2006-2007)[J]. Jpn J Clin Oncol,2010,40(8):795-799.
[24] 韩肖燕,紘明蓉,陈悦,等.宫颈腺癌27 例术前新辅助化疗近期疗效分析[J].癌症进展杂志,2009,7(2):184-188.
[25] Kim K,Kim MJ,Chung HH,et al.Inadvertent potential risk of neoadjuvant chemotherapy in cervical cancer [J].Med Hypotheses,2009,73(6):1005-1007.